Cetera Advisor Networks LLC Raises Position in GSK plc (NYSE:GSK)

Cetera Advisor Networks LLC increased its position in GSK plc (NYSE:GSKFree Report) by 5.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,787 shares of the pharmaceutical company’s stock after acquiring an additional 9,366 shares during the period. Cetera Advisor Networks LLC’s holdings in GSK were worth $6,515,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GSK. Sequoia Financial Advisors LLC raised its stake in shares of GSK by 11.2% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 15,692 shares of the pharmaceutical company’s stock valued at $569,000 after buying an additional 1,585 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in shares of GSK by 5.9% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 37,093 shares of the pharmaceutical company’s stock valued at $1,345,000 after acquiring an additional 2,053 shares during the period. Pathstone Family Office LLC grew its position in shares of GSK by 211.5% during the 3rd quarter. Pathstone Family Office LLC now owns 24,394 shares of the pharmaceutical company’s stock valued at $887,000 after acquiring an additional 16,563 shares during the period. HighTower Advisors LLC grew its position in shares of GSK by 7.3% during the 3rd quarter. HighTower Advisors LLC now owns 375,438 shares of the pharmaceutical company’s stock valued at $13,622,000 after acquiring an additional 25,662 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in shares of GSK during the 3rd quarter valued at about $85,000. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Trading Down 0.8 %

GSK stock opened at $41.21 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92. The stock has a market cap of $85.41 billion, a price-to-earnings ratio of 14.93, a PEG ratio of 1.25 and a beta of 0.66. The business’s 50-day moving average is $42.61 and its 200 day moving average is $40.74.

GSK (NYSE:GSKGet Free Report) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The business had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. On average, sell-side analysts anticipate that GSK plc will post 4.11 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a $0.3762 dividend. This represents a $1.50 dividend on an annualized basis and a yield of 3.65%. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend is Thursday, May 16th. GSK’s dividend payout ratio (DPR) is 53.26%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Guggenheim upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. The Goldman Sachs Group assumed coverage on GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Finally, Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of “Moderate Buy” and an average price target of $47.00.

View Our Latest Stock Report on GSK

GSK Company Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Featured Articles

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.